Syncona’s Autolus begins three T-cell cancer trials – DIGITALLOOK
|
Syncona's Autolus begins three T–cell cancer trials
DIGITALLOOK The second most commonly diagnosed blood cancer after non-Hodgkin lymphoma, multiple myeloma is a blood cancer affecting plasma cells which can currently be treated but not cured. AUTO2 is the first dual-targeting CAR–T cell therapy in clinical … Arix Bioscience notes positive progress by Autolus |
